Hammond C B, Jelovsek F R, Lee K L, Creasman W T, Parker R T
Am J Obstet Gynecol. 1979 Mar 1;133(5):537-47. doi: 10.1016/0002-9378(79)90289-8.
Two groups of hypoestrogenic women are analyzed by retrospective comparison. Patients were observed by a single group of physicians for at least five years -- 301 patients treated with replacement estrogen and 309 untreated patients. Of each group, 207 women had uteri in situ. Incidence figures for neoplasia (gynecologic, breast, and all sites) were compared between the two groups and with the Third National Cancer Survey, yielding a risk ratio for the development of adenocarcinoma of the endometrium among estrogen-treated women of 3.8 and 9.3, respectively. There was no increase among any other malignancies. The addition of synthetic progestin to estrogen therapy provided significant protection against the likelihood of developing endometrial cancer and did not reduce previously reported metabolic benefits of estrogen treatment. Data pertaining to estrogen use and details of the patients with endometrial carcinoma are presented.
通过回顾性比较分析两组雌激素水平低下的女性。由一组医生对患者进行至少五年的观察——301例接受雌激素替代治疗的患者和309例未接受治疗的患者。每组中，207名女性子宫原位存在。比较两组之间以及与第三次全国癌症调查中肿瘤（妇科、乳腺和所有部位）的发病率数据，结果显示接受雌激素治疗的女性发生子宫内膜腺癌的风险比分别为3.8和9.3。其他任何恶性肿瘤均无增加。在雌激素治疗中添加合成孕激素可显著降低发生子宫内膜癌的可能性，且未降低先前报道的雌激素治疗的代谢益处。文中呈现了与雌激素使用相关的数据以及子宫内膜癌患者的详细情况。
